<unk>  (trade name Aliqopa ; codenamed BAY 80-6946) is a drug which is approved by US FDA for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.<unk>  has been shown to have an effect against survival and spread of cancerous B-cells. Efficacy resulting in the approval of<unk>  was based on the subgroup of 104 patients with follicular lymphoma from a Phase 2 clinical trial. Of these, 59 percent had a complete or partial shrinkage of their tumors that lasted about 12 months. To assess the safety of the drug, data from 168 adults with follicular lymphoma and other hematologic malignancies treated with<unk>  were evaluated.<unk>  is administered as intravenous infusion on a weekly but intermittent schedule (three weeks on and one week off).<unk>  is currently approved only in the United States.
Copanlisib
Elixir
Rolapitant
Mitapivat
Nyasol
Cobicistat
Lazaretto
Abametapir